Pharma BD Deal Intelligence
A $1.3 billion deal that turned into a Phase 3 futility bust: Novo Nordisk halted ocedurenone's CLARION-CKD trial in 2024 and took a ~$0.8B impairment. Novo later accused KBP of concealing unfavorable Phase 2 data and won an asset freeze on KBP's chairman while seeking roughly $830 million back.
Novo Nordisk acquired KBP Biosciences for $1.3B for ocedurenone for hypertension.
Novo Nordisk stops the Phase 3 CLARION-CKD trial of ocedurenone after futility analysis on the primary endpoint and recognises an impairment loss of ~DKK…
Novo Nordisk seeks ~$830M from KBP Biosciences, alleging KBP concealed Phase 2 inefficacy data and trial-site irregularities; Singapore International…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Novo Nordisk agreed in October 2023 to acquire ocedurenone -- a non-steroidal mineralocorticoid receptor antagonist (MRA) for uncontrolled hypertension in patients with advanced chronic kidney disease -- from Singapore-based KBP Biosciences for up to $1.3 billion, with $1.3B in milestone-heavy consideration. The deal closed in December 2023. On 26 June 2024 Novo Nordisk stopped the Phase 3 CLARION-CKD trial after an independent data monitoring committee found it met prespecified futility criteria on the primary endpoint (change in systolic blood pressure at week 12), and recognised an impairment loss of approximately DKK 5.7 billion (~USD 0.8B). Novo discontinued ocedurenone development in November 2024. In a subsequent dispute, Novo Nordisk alleges KBP fraudulently concealed Phase 2 data showing the drug's inefficacy and quality/compliance irregularities at a key trial site; on 14 February 2025 the Singapore International Commercial Court found a 'good arguable case' and granted Novo's request to freeze the assets of KBP founder/chairman Huang Zhenhua, with Novo seeking roughly $830 million -- approximately what it had paid under the deal.
12M US cases/yr · $30.0B 2024 hypertension market
Ocedurenone Phase 3 CLARION-CKD failed futility; nonsteroidal MRA approach abandoned by Novo
Ocedurenone (nonsteroidal MRA) development was impacted by the CLARION-CKD futility analysis. The resistant/uncontrolled hypertension space includes Kerendia (finerenone) and spironolactone. Cardiorenal outcomes remain the key clinical endpoint for differentiation.
Novo Nordisk completed $1.3B acquisition of KBP Biosciences, gaining ocedurenone, non-steroidal MRA for hypertension.
Independent DMC found CLARION-CKD met prespecified futility criteria on the primary endpoint (systolic BP at week 12). Novo stopped the trial and recognised ~DKK 5.7B impairment (~$0.8B).
Novo discontinued ocedurenone in November 2024 following the CLARION-CKD futility stop; the non-steroidal MRA program was abandoned. (Corrects prior 'Phase 3 ongoing' status.)
Novo Nordisk alleges KBP concealed Phase 2 inefficacy data and trial-site irregularities; Singapore International Commercial Court found a 'good arguable case' and granted an asset freeze on KBP chairman Huang Zhenhua. Novo seeks ~$830M.
Ocedurenone expanded Novo beyond GLP-1/obesity into hypertension/cardiorenal, but the Phase 3 CLARION-CKD failure (futility, June 2024) and discontinuation -- now compounded by a $830M fraud action against KBP -- make this a value-destructive acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novo Nordisk A/S / KBP Biosciences (this deal) | 2023 | $1.3B | 26 |
| Novo Nordisk A/S / Emisphere Technologies | 2020 | $1.4B | 90 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2019 | $3.3B | 88 |
| Novo Nordisk A/S / Vivtex Inc. | 2026 | $2.1B | 69 |
| Novo Nordisk A/S / Dicerna Pharmaceuticals, Inc. | 2021 | $3.3B | 68 |
| Novo Nordisk A/S / Forma Therapeutics Holdings Inc. | 2022 | $1.1B | 68 |
| Novo Nordisk A/S / Inversago Pharma | 2023 | $1.1B | 61 |
← Browse all deals · How we score deals
More: 2023 deals · Novo Nordisk A/S deals · Cardiovascular deals